Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.

Abstract: A vehicle travel control method and a vehicle travel control device carries out a downshift control of an automatic transmission when a vehicle speed increases from a set vehicle speed during a constant speed travel control by at least a first prescribed value. Subsequent downshift control of the automatic transmission is prohibited upon determining the vehicle speed has increased from the set vehicle speed by at least the first prescribed value due to an operation of an operating element by the driver during constant speed travel control. Downshift control of the automatic transmission is executed upon determining insufficient deceleration of the vehicle exists where the driver is not operating the accelerator pedal during prohibition of the downshift control.

Abstract: A vehicle travel control method and a vehicle travel control device carries out a downshift control of an automatic transmission when a vehicle speed increases from a set vehicle speed during a constant speed travel control by at least a first prescribed value. Subsequent downshift control of the automatic transmission is prohibited upon determining the vehicle speed has increased from the set vehicle speed by at least the first prescribed value due to an operation of an operating element by the driver during constant speed travel control. Downshift control of the automatic transmission is executed upon determining insufficient deceleration of the vehicle exists where the driver is not operating the accelerator pedal during prohibition of the downshift control.

Abstract: A hybrid vehicle control device is provided for controlling a drive system. The hybrid vehicle control device is programmed to perform an engine start control using a motor/generator as an engine start motor when an engine start request is present. The hybrid vehicle control device includes a second clutch control section and an engine start control section. The second clutch control section completely disengages the second clutch. The engine start control section engages or slip engages of the first clutch, and performs engine start control resulting from performing an engine cranking operation, injecting air and fuel and igniting same. The hybrid vehicle control module disengages the first clutch and engages the second clutch during coasting/regenerating driving with the motor/generator while traveling in an electric vehicle mode when the engine start request is due to a driver input for an increase in a required driving force.

Abstract: A hybrid vehicle control device for a drive system is provided with an engine, a motor and an automatic transmission. The hybrid vehicle control device is configured such that when there is a mode switch request during an EV mode where only the motor is used as a drive source, a shift is made to an HEV mode where the engine and the motor are used as drive sources. The hybrid vehicle control device is further configured such that if a mode switch request and a downshift request for the automatic transmission (are generated, mode switch control is immediately started first. The configuration is also such that downshift control is started once the rotational speed of the engine has reached a combustion possible rotational speed, and the transmission speed at this time is made to be faster than an ordinary transmission speed.

Abstract: A hybrid vehicle control device is provided for controlling a drive system. The hybrid vehicle control device is programmed to perform an engine start control using a motor/generator as an engine start motor when an engine start request is present. The hybrid vehicle control device includes a second clutch control section and an engine start control section. The second clutch control section completely disengages the second clutch. The engine start control section engages or slip engages of the first clutch, and performs engine start control resulting from performing an engine cranking operation, injecting air and fuel and igniting same. The hybrid vehicle control module disengages the first clutch and engages the second clutch during coasting/regenerating driving with the motor/generator while traveling in an electric vehicle mode when the engine start request is due to a driver input for an increase in a required driving force.

Abstract: A hybrid vehicle control device for a drive system is provided with an engine, a motor and an automatic transmission. The hybrid vehicle control device is configured such that when there is a mode switch request during an EV mode where only the motor is used as a drive source, a shift is made to an HEV mode where the engine and the motor are used as drive sources. The hybrid vehicle control device is further configured such that if a mode switch request and a downshift request for the automatic transmission (are generated, mode switch control is immediately started first. The configuration is also such that downshift control is started once the rotational speed of the engine has reached a combustion possible rotational speed, and the transmission speed at this time is made to be faster than an ordinary transmission speed.

Abstract: The present invention provides a zero emission type method for effective use permitting economical and effective manufacture of zeolite effectively applicable in various sectors of industry by using silicon-containing waste comprising at least one of exhaust gas treatment sludge mainly comprising SiO2 discharged from an optical film manufacturing plant, optical fiber refuse and preform refuse, and aluminum-containing waste comprising at least one of aluminum dross discharged from an aluminum-related manufacturing plant, aluminum dust collection ashes, sludge mainly comprising aluminum hydroxide, cleaning waste liquid of aluminum or an alloy thereof, scrap of metal aluminum or an alloy thereof, and alumina scrap.

Abstract: The present invention provides a zero emission type method for effective use permitting economical and effective manufacture of zeolite effectively applicable in various sectors of industry by using silicon-containing waste comprising at least one of exhaust gas treatment sludge mainly comprising SiO2 discharged from an optical film manufacturing plant, optical fiber refuse and preform refuse, and aluminum-containing waste comprising at least one of aluminum dross discharged from an aluminum-related manufacturing plant, aluminum dust collection ashes, sludge mainly comprising aluminum hydroxide, cleaning waste liquid of aluminum or an alloy thereof, scrap of metal aluminum or an alloy thereof, and alumina scrap.

Abstract: An oligonucleotide containing a sequence of SEQ ID NO: 1: CAGTGAGTGG GTGGGGCTGG AACA, or SEQ ID NO: 2: TTAAGCTTTT ACCATGGTAA CCCC; a pharmaceutical composition comprising the oligonucleotide; and a method for treating or preventing a disease accompanied by an extracellular matrix deposition, are disclosed.

Abstract: A water-absorbent resin dispersion comprising a water-absorbent resin (B) or a hydrous gel thereof dispersed in a liquid or heat-meltable organic active-hydrogen compound (A), wherein said resin (B) is formed by the polymerization of a water-soluble monomer or its precursor and a cross-linker and/or a polysaccharide in the compound (A); and a process for producing a polyurethane resin by the reaction of the dispersion with an organic polyisocyanate compound. As the polyurethane resin is excellent in the capacity and rate of absorption, it is useful as absorbent articles such as paper diaper and sanitary goods, humidity modifiers, cutoff material, and so forth.

Abstract: A composition comprising as an active ingredient a compound consisting of an immunoglobulin F.sub.c fragment and an alkylating, antibiotic, or antimetabolic antitumor substance bound thereto, and a pharmaceutically acceptable carrier is disclosed. The Fc fragment moiety in the compound is stable in a living body, and thus the activity of the antitumor substance therein is maintained over a long period.

Abstract: Vibration-absorbing elastomeric composites, having improved vibration-damping properties with improved moldability and resin properties suitable for molded products, are obtained by reacting, insitu in a melted thermoplastic resin such as olefin-diene copolymer, a polyisocyanate with a polyol to form a polyurethane having a nitrogen atom content of at least 3% and having a solubility parameter which is higher by at least 2.5 than that of said thermoplastic resin.

Abstract: A novel imidazole derivative of the formula (I): ##STR1## wherein X.sub.1 is a chlorine or fluorine atom, or a hydroxy group or a salt thereof, and a pharmaceutical composition containing the same as the active ingredient.

Abstract: A method of inhibiting aromatase, comprising administering to a mammal in need thereof a pharmaceutical composition comprising an effective aromatase inhibiting amount of a compound of the formula (I): ##STR1## wherein X.sub.1 is a chlorine or fluorine atom, or a hydroxy group, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Abstract: A novel azole derivative of the general formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are, independently from each other, a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, x.sub.1 and x.sub.2 are, independently from each other, a hydrogen or halogen atom, or hydroxyl, cyano, or trifluoromethyl group, and Y is CH or a nitrogen atom, a process for the production thereof, and a pharmaceutical composition containing the same as the active ingredient.

Abstract: A novel azole derivative of the general formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are, independently from each other, a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, X.sub.1 and X.sub.2 are, independently from each other, a hydrogen or halogen atom, or hydroxyl, cyano, or trifluoromethyl group, and Y is CH or a nitrogen atom, a process for the production thereof, and a pharmaceutical composition containing the same as the active ingredient.

Abstract: A phenylalanine-glycine derivative of the general formula (I): ##STR1## wherein R represents a residue of an antitumor substance, or a salt or ester thereof, a process for preparation thereof, and a pharmaceutical composition containing the same are described.The novel conjugate of the phenylalanine-glycine derivative and the antitumor substance exhibits superior antitumor activity in comparison with the case wherein an antitumor substance is administered singly or as a mixture with phenylalanine.

Abstract: Azole derivatives (including stereoisomers and pharmaceutically acceptable salts) of the formula: ##STR1## wherein R.sub.1 and R.sub.2 each are H or C.sub.1 -C.sub.4 alkyl; R.sub.3 is H, OH, CN, halogen, haloalkyl, C.sub.1 -C.sub.4 alkyl or phenyl, and if there are two or more R.sub.3 groups, such R.sub.3 groups may be the same or different; n is an integer from 0 to 5; Y is N or CH; and X is O, S or NH have antimycotic and aromatase inhibitory activities. Compositions containing the azole derivatives and a method of treating mycosis and estrogen-dependent diseases by administering effective quantities of the azole derivatives are also disclosed.

Abstract: Azole derivatives (including stereoisomers and pharmaceutically acceptable salts) of the formula: ##STR1## wherein R.sub.1 and R.sub.2 each are H or C.sub.1 -C.sub.4 alkyl; R.sub.3 is H, OH, CN, halogen, haloalkyl, C.sub.1 -C.sub.4 alkyl or phenyl, and if there are two or more R.sub.3 groups, such R.sub.3 groups may be the same or different; n is an integer from 0 to 5; Y is N or CH; and X is O, S or NH have antimycotic and aromatase inhibitory activities. Compositions containing the azole derivatives and a method of treating mycosis and estrogen-dependent diseases by administering effective quantities of the azole derivatives are also disclosed.